Stockscreener 앱 받기
12.79
51.36%
4.34
시간 외 거래:
12.03
-0.76
-5.94%
전일 마감가:
$8.45
열려 있는:
$8.29
하루 거래량:
1.39M
Relative Volume:
2.23
시가총액:
$21.37M
수익:
-
순이익/손실:
$-13.52M
주가수익비율:
-17.28
EPS:
-0.74
순현금흐름:
$-10.03M
1주 성능:
+122.05%
1개월 성능:
+83.24%
6개월 성능:
+257.26%
1년 성능:
-53.41%
1일 변동 폭
$8.1122
$14.42
1주일 범위
$7.09
$14.42
52주 변동 폭
$2.86
$29.00
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
명칭
Kazia Therapeutics Limited Adr
전화
01161298780088
주소
140 WICKS RD, NEW SOUTH WALES 2113, NSW
KZIA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KZIA
Kazia Therapeutics Limited Adr
|
12.79 | 14.12M | 0 | -13.52M | -10.03M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-06 | 개시 | Maxim Group | Buy |
| 2021-10-14 | 개시 | Maxim Group | Buy |
| 2021-01-05 | 개시 | H.C. Wainwright | Buy |
Kazia Therapeutics Limited Adr 주식(KZIA)의 최신 뉴스
Kazia Therapeutics Limited (KZIA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kazia Therapeutics reports immune complete response in TNBC - MSN
KZIA Shares Surge: Can This Momentum Last? - StocksToTrade
Kazia Therapeutics (KZIA) Stock Soars on Breakthrough Results in Breast Cancer Treatment - parameter.io
You might want to take a look at Kazia Therapeutics Limited ADR (KZIA) now - Setenews
Kazia Therapeutics receives Nasdaq delisting notice, plans to request hearing By Investing.com - Investing.com India
Kazia Therapeutics receives Nasdaq delisting notice, plans to request hearing - Investing.com
Kazia Therapeutics Achieves Initial iCR… - digitalmore.co
Kazia reports immune-complete response in metastatic breast cancer By Investing.com - Investing.com South Africa
Kazia reports immune-complete response in metastatic breast cancer - Investing.com
Kazia stock soars after patient shows complete response in TNBC trial - Investing.com Nigeria
[424B3] KAZIA THERAPEUTICS LTD Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Kazia (Nasdaq: KZIA) reports iCR in metastatic TNBC and outlines Q4 oncology pipeline - Stock Titan
[6-K] KAZIA THERAPEUTICS LTD Current Report (Foreign Issuer) | KZIA SEC FilingForm 6-K - Stock Titan
[20-F] KAZIA THERAPEUTICS LTD Files Annual Report (Foreign Issuer) | KZIA SEC FilingForm 20-F - Stock Titan
How Does Wall Street Rate Shares Of DoubleDown Interactive Co Ltd ADR (DDI)? - fostersleader.com
Is Buying Stock In MediWound Ltd (MDWD) A Good Move Today? - fostersleader.com
Kazia Therapeutics stock seeks FDA guidance on paxalisib approval path - Investing.com
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner - Benzinga
Kazia (NASDAQ: KZIA) to request FDA Type C on GBM OS; NDA path under review - Stock Titan
Kazia (KZIA) secures PD-L1 degrader NDL2 with $1.39M payment - Stock Titan
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program - Stock Titan
KZIA Stock Institutional Owners - Quiver Quantitative
Kazia reports 86% tumor reduction in expanded access case - Investing.com India
86% Tumor Reduction: Kazia's Experimental Cancer Drug Paxalisib Shows Dramatic Results in TNBC Patient Study - Stock Titan
Revolutionary AI Platform to Combat 25% of Childhood Brain Cancer Deaths: Kazia's New Research Initiative - Stock Titan
Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG - Ariva
Kazia Therapeutics Achieves Breakthrough in Breast Cancer Treatment with Paxalisib - The Globe and Mail
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy - The Manila Times
100% Cancer Cell Cluster Elimination: Kazia's Breakthrough Drug Shows Perfect Score in Advanced Breast Cancer - Stock Titan
Leptomeningeal Metastases Market to Exhibit Growth at a - GlobeNewswire
Novogen Limited (NASDAQ:KZIA) Sees Large Growth in Short Interest - Defense World
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market - The Manila Times
Kazia Therapeutics raises US$2m via discounted private placement to fund trials | KZIA SEC FilingForm 6-K - Stock Titan
Kazia Therapeutics Announces At the Market Offering Agreement - The Globe and Mail
Kazia Therapeutics starts US$1.9M ATM ADS program; CEO exits board | KZIA SEC FilingForm 6-K - Stock Titan
Glioblastoma Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Treatment, Therapies and Companies by DelveInsight - Barchart.com
Novogen (NASDAQ:KZIA) Raised to “Sell” at Wall Street Zen - ETF Daily News
Analysts Issue Forecasts for Novogen FY2025 Earnings - Defense World
Novogen (NASDAQ:KZIA) Upgraded by HC Wainwright to Strong-Buy Rating - Defense World
Novogen (NASDAQ:KZIA) Rating Increased to Strong-Buy at HC Wainwright - Defense World
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - The Globe and Mail
Phase 1b Data Suggest Paxalisib Combo May Suppress CTCs in Metastatic TNBC - Targeted Oncology
Novogen (NASDAQ:KZIA) Shares Up 39.7% – Should You Buy? - Defense World
Ryde Group files US$100 M shelf; micro-cap float limits near-term raise | KZIA SEC FilingForm 424B3 - Stock Titan
Cancer Innovation Accelerates As Funding Cuts Loom And Biotechs Step Up - Barchart.com
Kazia Therapeutics stock soars after positive early cancer treatment data By Investing.com - Investing.com Nigeria
Kazia Therapeutics stock soars after positive early cancer treatment data - Investing.com Australia
Early Clinical Trial: New Drug Combo Slashes Breast Cancer Cells by 50% in Just 21 Days - Stock Titan
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial - Ariva
Short Interest in Novogen Limited (NASDAQ:KZIA) Declines By 28.0% - Defense World
Kazia Therapeutics Limited Adr (KZIA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.53%
1.88%
자본화:
|
볼륨(24시간):